Rockefeller Capital Management
RNTX

Rockefeller Capital Management’s Rein Therapeutics RNTX Stock Holding History

Rockefeller Capital Management’s Portfolio RNTX Stock Details RNTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.3K Hold
5,097
– – ﹤0.01% 4227
2026
Q1 		$6.63K Hold
5,097
– – ﹤0.01% 4154
2025
Q4 		$5.91K Hold
5,097
– – ﹤0.01% 4014
2025
Q3 		$5.84K Buy
+5,097
New +$6.47K ﹤0.01% 3826
2023
Q1 		– Sell
-50
Closed – – 3962
2022
Q4 		$0 Hold
50
– – ﹤0.01% 4273
2022
Q3 		$0 Hold
50
– – ﹤0.01% 4459
2022
Q2 		$0 Hold
50
– – ﹤0.01% 4443
2022
Q1 		$0 Buy
+50
New +$453 ﹤0.01% 4100

Other funds holding RNTX

VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
CCC
Cable Car Capital San Francisco, California $4.66B AUM 77.16% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $164M AUM 542.31% 1-Year Est. Return
SM
Senvest Management New York $3.41B AUM 66.27% 1-Year Est. Return

Rockefeller Capital Management's RNTX Position: Q2 2026 in Review

Rockefeller Capital Management held its Rein Therapeutics (RNTX) position steady in Q2 2026 at 5,097 shares worth $5.3K. The position accounts for ﹤0.01% of the portfolio, ranked #4227.

Rockefeller Capital Management first reported a position in RNTX in Q1 2022 and has held it in 8 quarters since. The position peaked at $6.63K in Q1 2026. 60 funds tracked by Wall St. Rank hold RNTX as of Q2 2026.

  • Rockefeller Capital Management held 5,097 shares of Rein Therapeutics worth $5.3K as of Q2 2026.
  • Rockefeller Capital Management left its Rein Therapeutics share count unchanged in Q2 2026.
  • Rein Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q2 2026, its #4227 holding.
  • Rockefeller Capital Management first reported a position in Rein Therapeutics in Q1 2022 and has held it in 8 quarters since.
  • Rockefeller Capital Management's Rein Therapeutics position peaked at $6.63K in Q1 2026.
  • 60 funds tracked by Wall St. Rank held Rein Therapeutics as of Q2 2026.

Based on Rockefeller Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.